Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Headlines
    3. >Trump says price of Ozempic will be lowered
    Headlines

    Trump Says Price of Ozempic Will Be Lowered

    Published by Global Banking & Finance Review®

    Posted on October 16, 2025

    2 min read

    Last updated: January 21, 2026

    Add as preferred source on Google
    Trump says price of Ozempic will be lowered - Headlines news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:Presidenthealthcareinsurancefinancial management

    Quick Summary

    President Trump announced plans to lower the price of Ozempic, a drug by Novo Nordisk, from $1,300 to $150, impacting diabetes and obesity treatments.

    Trump Announces Plans to Reduce Ozempic Drug Prices Significantly

    Trump's Announcement on Ozempic Pricing

    WASHINGTON (Reuters) -U.S. President Donald Trump said on Thursday that the price of Novo Nordisk's best-selling weight-loss drug would be lowered and that negotiations over price changes would be swift.

    Details of the Price Reduction

    Trump made the comments during a White House event on fertility treatments and drug pricing. He was asked by reporters to identify the name of a drug that he earlier in the event said would be made less expensive.

    Impact on Healthcare and Patients

    "I was referring to Ozempic, or - I was referring to - the fat loss drug?.... They'll be much lower," Trump said.

    Negotiation Process for GLP-1 Drugs

    Novo sells Ozempic for managing diabetes while Wegovy is approved for weight-loss. Both drugs contain the same active ingredient, semaglutide.

    Role of Medicare and Medicaid Services

    The company was not immediately available for comment.

    Trump earlier said that under his administration's plans, the price of the drug would be reduced to $150 from $1,300. Ozempic has a list price of about $1,000 for a month's supply but is sold directly by Novo to cash-pay customers for $499 per month.

    During the same White House event, Dr. Mehmet Oz, who runs the Centers for Medicare and Medicaid Services, said that the agency had not yet finished negotiating the price for GLP-1 drugs, which are used to treat diabetes and obesity.

    Novo's Ozempic is one of the drugs that the agency has chosen for price negotiations.

    (Reporting by Trevor Hunnicutt with additional reporting by Patrick Wingrove; Editing by Rami Ayyub and Caroline Humer)

    Table of Contents

    • Trump's Announcement on Ozempic Pricing
    • Details of the Price Reduction
    • Impact on Healthcare and Patients
    • Negotiation Process for GLP-1 Drugs
    • Role of Medicare and Medicaid Services

    Key Takeaways

    • •Trump plans to reduce Ozempic price significantly.
    • •Negotiations on drug pricing to be swift.
    • •Ozempic is used for diabetes and weight loss.
    • •Novo Nordisk sells Ozempic and Wegovy.
    • •Medicare and Medicaid Services involved in pricing.

    Frequently Asked Questions about Trump says price of Ozempic will be lowered

    1What is Wegovy?

    Wegovy is a prescription medication specifically approved for weight loss, also containing semaglutide, the same active ingredient as Ozempic.

    More from Headlines

    Explore more articles in the Headlines category

    Image for Denmark's Frederiksen faces tough coalition talks to remain prime minister
    Denmark's Frederiksen Faces Tough Coalition Talks to Remain Prime Minister
    Image for UK police arrest two men over arson attack on Jewish community ambulances
    UK Police Arrest Two Men Over Arson Attack on Jewish Community Ambulances
    Image for Cricket-Bairstow joins Livingstone in criticising level of care in England set-up
    Cricket-Bairstow Joins Livingstone in Criticising Level of Care in England Set-Up
    Image for Mullally to be installed as first female Archbishop of Canterbury
    Mullally to Be Installed as First Female Archbishop of Canterbury
    Image for Cyprus seeks new security deal for UK bases, Telegraph reports
    Cyprus Seeks New Security Deal for UK Bases, Telegraph Reports
    Image for British army veteran completes record 100km Land Rover pull
    British Army Veteran Completes Record 100km Land Rover Pull
    Image for Pope Leo laments that Iran war 'getting worse and worse'
    Pope Leo Laments That Iran War 'getting Worse and Worse'
    Image for Denmark's left-wing bloc leads election but lacks majority, exit polls show
    Denmark's Left-Wing Bloc Leads Election but Lacks Majority, Exit Polls Show
    Image for Moldovan parliament backs energy state of emergency after power line put out of action
    Moldovan Parliament Backs Energy State of Emergency After Power Line Put Out of Action
    Image for US expected to send thousands more soldiers to Middle East, sources say
    US Expected to Send Thousands More Soldiers to Middle East, Sources Say
    Image for Brazil court places Bolsonaro under house arrest on health grounds
    Brazil Court Places Bolsonaro Under House Arrest on Health Grounds
    Image for Analysis-Gulf warnings and fears of miscalculation preceded Trump’s pause in Iran showdown
    Analysis-Gulf Warnings and Fears of Miscalculation Preceded Trump’s Pause in Iran Showdown
    View All Headlines Posts
    Previous Headlines PostTrump, Merck KGaA Announce Deal to Cut Some Ivf Drug Prices
    Next Headlines PostRussian Journalist Killed by Ukrainian Drone, His Media Outlet Says